Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tranexamic acid (TA) inhibits fibrinolysis by binding to lysine binding-sites of plasminogen to fibrin. Fibrinolysis is stimulated by surgical trauma, and the administration of TA has been shown effective in decreasing blood loss both intra-operatively and in the immediate post-operative period in elective hip and knee arthroplasty patients. Both the timing and dosing of TA has been investigated in these patients. Subsequent blood transfusion rate has also been shown to decrease as result of TA administration. Despite the support for TA utilization that exists in the arthroplasty literature, the data is scarce regarding its administration during surgical treatment of hip fractures. This is patient population who is at high risk for transfusion due to symptomatic post-operative anemia. This study aims to investigate whether TA's advantageous effects in the arthroplasty patient population can be extrapolated to the more unstable, heterogeneous hip fracture patient population. If the study is able to show a difference in blood loss and transfusion requirement, the long term implications of this with regards to cost and mortality can be significant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement

NCT03182751

Hip Fractures Intertrochanteric Fractures

COMPLETED PHASE2

Tranexamic Acid Use in Acute Hip Fractures

NCT02947529

Acute Hip Fractures

COMPLETED PHASE4

Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures

NCT05518279

Hip Fractures Blood Loss

WITHDRAWN PHASE3

Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures

NCT02580227

Hip Fractures Surgical Blood Loss

UNKNOWN PHASE4

Effect of Early Administration of TXA in Adult Hip Fractures

NCT05047133

Postoperative Blood Loss

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hip Fracture

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Group Type PLACEBO_COMPARATOR

Control: Saline

Intervention Type DRUG

Interventional

Group Type ACTIVE_COMPARATOR

Tranexamic Acid

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control: Saline

Intervention Type DRUG

Tranexamic Acid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients admitted to Bryn Mawr Hospital with fracture of the femoral neck, intertrochanteric region, or subtrochanteric region of the femur will be considered for the study.

Exclusion Criteria

* age under 18
* allergy to TA
* known current or history of venous thromboembolism (VTE)
* history of known coagulopathy or bleeding disorder
* current subarachnoid hemorrhage
* previous history of seizures
* current use of estrogen/progesterone therapy
* renal failure defined as creatinine clearance less than 30 ml/min4
* multiple fractures
* pregnant or breastfeeding women
* planned nonoperative management of the fracture

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No